Evommune EVMN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Evommune in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evommune 's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evommune 's cash & equivalents?
- Evommune (EVMN) reported cash & equivalents of $1.07M in Q1 2026.
- How has Evommune 's cash & equivalents changed year-over-year?
- Evommune 's cash & equivalents increased by 401.1% year-over-year, from $213.63K to $1.07M.
- What is the long-term trend for Evommune 's cash & equivalents?
- Over 2 years (2023 to 2025), Evommune 's cash & equivalents has grown at a 169.7% compound annual growth rate (CAGR), from $374.44K to $2.72M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.